SLC22A2 and leukemia: Among these TKIs, dasatinib18, 27, an oral Bcr-Abl and Src-family kinase inhibitor approved for the treatment of leukaemia, was found to be the most potent OCT2 inhibitor (Fig. 1c), with OCT2 inhibition seen at nanomolar concentrations (Fig. 1d).